अमूर्त
Nilotinib for treatment of chronic myeloid leukemia in light of the current evidence and guidelines
Pratap Neelakantan, Jane F Apperley The introduction of the tyrosine kinase inhibitor imatinib, a little over a decade
ago, has greatly improved the prognosis for patients with chronic myeloid leukemia. Now
with the availability of second-generation tyrosine kinase inhibitors we anticipate further
improvements in the outcome of this disease. These agents, namely nilotinib, dasatinib and
bosutinib, have not only been effective at treatment of imatinib-resistant and/or -intolerant
patients, but are increasingly being advocated for upfront usage. In this review, we focus on
nilotinib, its pharmacology, clinical indications and side effects, and suggest guidelines for its
usage.
अस्वीकृति: इस सारांश का अनुवाद कृत्रिम बुद्धिमत्ता उपकरणों का उपयोग करके किया गया है और इसे अभी तक समीक्षा या सत्यापित नहीं किया गया है।